Search results for "Aspirin"
Many older adults use aspirin for primary prevention despite guideline changes
In 2021, nearly 30% of adults ages 60 years and older used aspirin for primary cardiovascular disease prevention despite 2018/2019 guideline updates from the American College of Cardiology and the American Heart Association.
https://immattersacp.org/weekly/archives/2024/06/25/1.htm
25 Jun 2024
Low-dose aspirin associated with 20% increase in risk of anemia among older adults
Analysis of a randomized trial of aspirin in healthy older patients found significantly increased risk of anemia, faster decline in hemoglobin concentrations, and greater decline in ferritin levels with aspirin versus placebo.
https://immattersacp.org/weekly/archives/2023/06/20/1.htm
20 Jun 2023
USPSTF pulls back on recommendation of low-dose aspirin for primary prevention
In a draft recommendation statement, the U.S. Preventive Services Task Force (USPSTF) now recommends against initiating low-dose aspirin for the primary prevention of cardiovascular disease in adults ages 60 years or older and says use should be an individual decision in patients ages 40 to 59 years.
https://immattersacp.org/weekly/archives/2021/10/19/5.htm
19 Oct 2021
Aspirin may benefit some people without cardiovascular disease, new analysis finds
An editorial accompanying the study concluded that it is reasonable to recommend aspirin for the primary prevention of cardiovascular disease in select patients, including those who are at high risk for cardiovascular disease with low bleeding risk.
https://immattersacp.org/weekly/archives/2019/09/17/4.htm
17 Sep 2019
Warfarin-aspirin therapy associated with increased bleeding compared with warfarin only
Patients with atrial fibrillation or venous thromboembolism who received aspirin without a clear therapeutic indication in addition to warfarin had higher rates of bleeding and similar rates of thrombosis.
https://immattersacp.org/weekly/archives/2019/03/12/2.htm
12 Mar 2019
Aspirin associated with fewer CV events, more major bleeding in healthy patients, review finds
When weighing the risks and benefits of aspirin for primary cardiovascular (CV) prevention in individual patients, clinicians must also consider other interventions that may lower risk, an accompanying editorial said.
https://immattersacp.org/weekly/archives/2019/01/29/1.htm
29 Jan 2019
Low-dose aspirin's effects on survival may come with caveats
A trial was stopped early after researchers determined that continued aspirin use appeared to yield no benefit.
https://immattersacp.org/weekly/archives/2018/09/18/2.htm
18 Sep 2018
Task Force recommends aspirin for primary prevention of CVD, colorectal cancer
The Task Force recommended that low-dose aspirin be initiated for the primary prevention of CVD and colorectal cancer in adults ages 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.
https://immattersacp.org/weekly/archives/2016/04/12/1.htm
12 Apr 2016